Q-omics provides the consensus-scored ELOA-AS1 profile across patient tissues and cancer cell-line models. ELOA-AS1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, ELOA-AS1 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, ELOA-AS1 RNA expression shows 19,468 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight READ, THCA, and ACC as cancer lineages where ELOA-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOA-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOA-AS1 survival associations across molecular data types. ELOA-AS1 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOA-AS1 RNA expression–survival associations across cancer types. High ELOA-AS1 expression shows unfavorable associations in KICH, LGG, ACC and KIRP, but favorable associations in READ and LUAD. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for ELOA-AS1 RNA expression.
This table summarizes ELOA-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ELOA-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOA-AS1 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LUSC, COAD and KIRC. The THCA box plot shows higher ELOA-AS1 RNA expression in normal versus tumor tissue (log2 FC = −0.647, t-test p < 0.001).
This table shows molecular features associated with ELOA-AS1 in patient tissues and cancer cell lines. In patient samples, ELOA-AS1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ELOA-AS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
